Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 3/20 | 0.60 |
| ▸ | REN | P00797 | 1/20 | 0.58 |
| ▸ | PSMB10 | P40306 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 10/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 8/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833552 | 0.92 | BCL2 (0.68) | BCL2RENPSMB10PTPN1PSMB1 | |
| SCHEMBL5833558 | 0.92 | BCL2 (0.68) | BCL2RENPSMB10PTPN1PSMB1 | |
| SCHEMBL7366740 | 0.88 | PSMB1 (0.62) | BCL2PSMB10PTPN1PSMB1PSMB9 | |
| SCHEMBL5833943 | 0.87 | MME (0.52) | BCL2PSMB10PSMB1PSMB9PSMB5 | |
| SCHEMBL5833946 | 0.87 | MME (0.52) | BCL2PSMB10PSMB1PSMB9PSMB5 | |
| SCHEMBL5833134 | 0.86 | MME (0.50) | BCL2RENPSMB10PSMB1PSMB9 | |
| SCHEMBL5833138 | 0.86 | MME (0.50) | BCL2RENPSMB10PSMB1PSMB9 | |
| SCHEMBL5833128 | 0.84 | BCL2 (0.53) | BCL2RENPSMB10PTPN1PSMB1 | |
| SCHEMBL7355021 | 0.84 | BCL2 (0.53) | BCL2RENPSMB10PTPN1PSMB1 | |
| SCHEMBL7283532 | 0.83 | MMP9 (0.69) | BCL2RENPSMB10PTPN1PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | BCL2 1044/4885REN 3074/4885PSMB10 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.